Jump to content


Hang onto your hat: Sclero Forums Upgrade May 14-21, 2017!! The Forums will be offline for up to 4 days, and then will return with an entirely new look and feel.


Photo

Safety, Tolerability and Pharmcodynamic Profile of Oral 2101 Once Daily for up to 14 Days in Secondary Raynaud's Disease


  • Please log in to reply
No replies to this topic

#1 janey

janey

    Platinum Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 2,113 posts
  • Location:New Mexico

Posted 03 November 2008 - 03:49 AM

Safety, Tolerability and Pharmcodynamic Profile of Oral 2101 Once Daily for up to 14 Days in Secondary Raynaud's Disease.

To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period. Currently Recruiting. University des Saarlandes. Homburg, Germany. ClinicalTrials.gov. (Also see: Raynaud's)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Janey Willis
ISN Support Specialist
(Retired) ISN Assistant Webmaster
(Retired) ISN News Director
(Retired) ISN Technical Writer for Training Manuals
International Scleroderma Network (ISN)